THU0325 Secukinumab demonstrates a consistent safety profile with up to 5 years treatment in patients with psoriatic arthritis and moderate to severe plaque psoriasis: updated pooled safety analyses
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.2308
Abstract: Background Pooled safety data from secukinumab (SEC) studies in psoriasis and psoriatic arthritis (PsA) have been reported previously.1 Objectives To report updated longer-term safety data with up to 5 years of SEC treatment from psoriasis… read more here.
Keywords: abbvie amgen; amgen bms; safety; psoriasis ... See more keywords